Llovet Josep M, Lencioni Riccardo
Translational Research in Hepatic Oncology Group, Liver Unit, IDIBAPS, Hospital Clinic Barcelona, University of Barcelona, Barcelona, Catalonia, Spain; Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain.
Department of Radiology, University of Pisa, Pisa, Italy; Miami Cancer Institute, Miami, FL, USA.
J Hepatol. 2020 Feb;72(2):288-306. doi: 10.1016/j.jhep.2019.09.026.
In 2010, modified RECIST (mRECIST) criteria were proposed as a way of adapting the RECIST criteria to the particularities of hepatocellular carcinoma (HCC). We intended to overcome some limitations of RECIST in measuring tumour shrinkage with local and systemic therapies, and also to refine the assessment of progression that could be misinterpreted with conventional RECIST 1.1, due to clinical events related to the natural progression of chronic liver disease (development of ascites, enlargement of lymph nodes, etc.). mRECIST has served its purpose since being adopted or included in clinical practice guidelines (European, American and Asian) for the management of HCC; it has also been instrumental for assessing response and time-to-event endpoints in several phase II and III investigations. Nowadays, mRECIST has become the standard tool for measurement of radiological endpoints at early/intermediate stages of HCC. At advanced stages, guidelines recommend both methods. mRECIST has been proven to capture higher objective response rates in tumours treated with molecular therapies and those responses have shown to be independently associated with better survival. With the advent of novel treatment approaches (i.e. immunotherapy) and combination therapies there is a need to further refine and clarify some concepts around the performance of mRECIST. Similarly, changes in the landscape of standard of care at advanced stages of the disease are pointing towards progression-free survival as a potential primary endpoint in some phase III investigations, as effective therapies applied beyond progression might mask overall survival results. Strict recommendations for adopting this endpoint have been reported. Overall, we review the performance of mRECIST during the last decade, incorporating novel clarifications and refinements in light of emerging challenges in the study and management of HCC.
2010年,改良的实体瘤疗效评价标准(mRECIST)被提出,作为使RECIST标准适应肝细胞癌(HCC)特殊性的一种方法。我们旨在克服RECIST在评估局部和全身治疗后肿瘤缩小方面的一些局限性,同时完善对疾病进展的评估,因为与慢性肝病自然进展相关的临床事件(腹水形成、淋巴结肿大等)可能导致传统的RECIST 1.1标准对疾病进展的评估出现误解。自被采用或纳入HCC管理的临床实践指南(欧洲、美国和亚洲)以来,mRECIST已发挥了其作用;它在多项II期和III期研究中对评估疗效和事件发生时间终点也起到了重要作用。如今,mRECIST已成为HCC早期/中期放射学终点测量的标准工具。在晚期,指南推荐同时使用两种方法。已证明mRECIST能在接受分子治疗的肿瘤中获得更高的客观缓解率,且这些缓解与更好的生存率独立相关。随着新型治疗方法(如免疫治疗)和联合治疗的出现,有必要进一步完善和阐明围绕mRECIST性能的一些概念。同样,疾病晚期治疗标准的变化表明,无进展生存期可能成为一些III期研究的潜在主要终点,因为在疾病进展后应用的有效治疗可能掩盖总生存期结果。已有关于采用该终点的严格建议的报道。总体而言,我们回顾了mRECIST在过去十年中的性能,并根据HCC研究和管理中出现的新挑战纳入了新的澄清和完善内容。